VRT-043198

CAT: 0804-HY-112226-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-112226-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
VRT-043198, the agent metabolite of VX-765 (Belnacasan), is a potent, selective and blood-brain barrier permeable inhibitor of interleukin-converting enzyme/caspase-1 subfamily caspases. VRT-043198 exhibits Ki values of 0.8 nM and 0.6 nM for ICE/caspase-1 and caspase-4, respectively[1].
CAS Number
[244133-31-1]
UNSPSC
12352005
Target
Caspase; Drug Metabolite
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/vrt-043198.html
Purity
98.89
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N[C@H](C=O)CC(O)=O)[C@H]1N(C([C@H](C(C)(C)C)NC(C2=CC=C(N)C(Cl)=C2)=O)=O)CCC1
Molecular Formula
C22H29ClN4O6
Molecular Weight
480.94
References & Citations
[1]Woods Wannamaker, et al. (S) -1- ((S) -2-{[1- (4-amino-3-chloro-phenyl) -methanoyl]-amino}-3,3-dimethyl-butanoyl) -pyrrolidine-2-carboxylic acid ((2R,3S) -2-ethoxy-5-oxo-tetrahydro-furan-3-yl) -amide (VX-765), an orally available selective interleukin (IL) -converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007 May;321 (2) :509-16.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Caspase 1; Caspase 4

Popular Products